

Optic radiation damage in multiple sclerosis is associated with visual dysfunction and retinal thinning – an ultrahigh-field MR pilot study

Tim Sinnecker · Timm Oberwahrenbrock · Imke Metz · Hanna Zimmermann · Caspar F. Pfueller · Lutz Harms · Klemens Ruprecht · Caren Ramien · Katrin Hahn · Wolfgang Brück · Thoralf Niendorf · Friedemann Paul · Alexander U. Brandt · Jan Dörr · Jens Wuerfel

Received: 4 March 2014 / Revised: 18 June 2014 / Accepted: 17 July 2014 / Published online: 17 August 2014
© European Society of Radiology 2014

Abstract

Objective To investigate posterior visual pathway damage in multiple sclerosis using ultrahigh-field magnetic resonance imaging (MRI) at 7 Tesla (7 T), and to determine its correlation with visual disability and retinal fibre layer (RNFL) damage detectable by optic coherence tomography (OCT).

Methods We studied 7 T MRI, OCT, functional acuity contrast testing (FACT), and visually evoked potentials (VEP, n=16) in 30 patients (including 26 relapsing-remitting MS and four clinically isolated syndrome patients) and 12 healthy controls to quantify RNFL thickness, optic radiation lesion volume, and optic radiation thickness.

Results Optic radiation lesion volume was associated with thinning of the optic radiation ($p<0.001$), delayed VEP ($p=0.031$), and visual disability indicated by FACT ($p=0.020$). Furthermore, we observed an inverse correlation between optic radiation lesion volume and RNFL thickness ($p<0.001$), including patients without previous optic neuritis ($p<0.001$).

Conclusions Anterior visual pathway damage, but also (subclinical) optic radiation integrity loss detectable by 7 T MRI are common findings in MS that are mutually affected. Given the association between optic radiation damage, visual impairment, and increased VEP latency in this exploratory study of a limited sample size, clinicians should be aware of

Jan Dörr and Jens Wuerfel are equally contributing senior authors

Electronic supplementary material The online version of this article (doi:10.1007/s00330-014-3358-8) contains supplementary material, which is available to authorized users.

T. Sinnecker · T. Oberwahrenbrock · H. Zimmermann · C. F. Pfueller · C. Ramien · F. Paul (✉) · A. U. Brandt · J. Dörr · J. Wuerfel
NeuroCure Clinical Research Center, Charité - Universitaetsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
e-mail: Friedemann.Paul@charite.de

T. Sinnecker
Department of Neurology, Asklepios Fachklinikum Teupitz, Teupitz, Germany

I. Metz · W. Brück
Institute of Neuropathology, University Medicine Goettingen, Goettingen, Germany

C. F. Pfueller · L. Harms · K. Ruprecht · F. Paul · J. Dörr
Clinical and Experimental Multiple Sclerosis Research Center, Charité - Universitaetsmedizin Berlin, Berlin, Germany

L. Harms · K. Ruprecht · K. Hahn · F. Paul
Department of Neurology, Charité - Universitaetsmedizin Berlin, Berlin, Germany

T. Niendorf · J. Wuerfel
Berlin Ultrahigh Field Facility (B.U.F.F.), Max Delbrueck Center for Molecular Medicine, Berlin, Germany

T. Niendorf · F. Paul
Experimental and Clinical Research Center, Charité - Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany

J. Wuerfel
Institute of Neuroradiology, University Medicine Goettingen, Goettingen, Germany

acute lesions within the optic radiation in patients with (bilateral) visual disturbances.

Key Points

- Focal destruction of the optic radiation is detectable by 7 T MRI.
- Focal optic radiation damage is common in MS.
- Optic radiation damage is associated with RNFL thinning, detectable by OCT.
- Optic radiation damage is associated with delayed VEP and visual dysfunction.
- RNFL thickness in non-optic neuritis eyes correlates with optic radiation demyelination.

Keywords Multiple sclerosis · Magnetic resonance imaging · Retinal nerve fibre layer · Optic radiation · Trans-synaptic degeneration

Introduction

Multiple sclerosis (MS) is considered an inflammatory demyelinating and neurodegenerative central nervous system disorder. The underlying pathophysiology of axonal loss [1–3], however, has remained unclear, impeding the development of neuroprotective drugs.

The visual system is highly susceptible to MS related damage. Visual disturbances are frequent and cause serious disability, but imaging of the visual pathway posterior to the optic chiasm – comprising the optic radiation (OR) – has remained challenging due to technical limitations. The OR as part of the posterior visual pathway transmits information from the ipsilateral temporal and contralateral nasal hemiretinae, projecting from interneurons of the lateral geniculate nucleus (LGN) to the striate cortex. The LGN, in turn, directly receives axons from retinal ganglion cells. These large and highly myelinated axons pass through the periventricular white matter [4, 5], being susceptible to focal inflammatory damage in MS.

Diffusion tensor imaging (DTI) recently enabled the examination of OR integrity loss, but could not visualise focal demyelination. Today, owing to increased susceptibility effects and a very high signal-to-noise ratio, high resolution magnetic resonance imaging (MRI) at 7 Tesla (7 T) [6, 7] picks up alterations of MS brain parenchyma with great anatomical details, and hence facilitates the distinction between MS and non-MS lesions, e.g. of vascular origin [8–10], lesions in patients with Susac syndrome [11, 12], or neuromyelitis optica [13]. Moreover, 7 T MRI delineates the OR against surrounding white matter with great distinction. The anatomical details revealed by T2* weighted (T2*w) fast low angle shot (FLASH) provides an opportunity not only to visualise, but also to quantify focal damage causing OR integrity loss.

In addition, retinal nerve fibre layer (RNFL) thinning detectable by optical coherence tomography (OCT) [14–16], delayed visually evoked potentials (VEP) [17], and visual dysfunction [16, 18] also in MS patients without a history of ON may indicate subclinical damage to the visual system.

Realising the excellent visibility of the OR in 7 T T2*w MRI, we aimed to quantify (subclinical) focal damage and atrophy of the optic radiation in MS. Furthermore, we investigated whether focal damage of the OR is related to delayed VEP, impaired visual function, OR thickness, and RNFL thinning in eyes with and without history of ON.

Materials and methods

Study participants

Patients with relapsing-remitting (RR) MS according to the 2010 panel criteria [1], or with clinically isolated syndrome (CIS) without history of ON were consecutively and prospectively enrolled between March 2010 and December 2012 at the Clinical and Experimental MS Research Center at the Charité-Universitaetsmedizin Berlin, Germany. Inclusion criteria were 1) RRMS disease course or patients with CIS who were aged 18 to 80 years and 2) informed written consent. Exclusion criteria were any contraindication for ultrahigh-field MRI at 7 T (e.g. pacemaker, claustrophobia or pregnancy). Patients underwent 7 T MRI at the Berlin Ultrahigh Field Facility (B.U.F.F.). In addition, OCT, functional acuity contrast testing (FACT), and VEP were performed during the routine workup at the NeuroCure Clinical Research Center (NCRC) by investigators that were not involved in MR imaging. VEP, OCT, and FACT investigators were not blinded with respect to clinical data. OCT and FACT were usually performed on the same day or within two days. Patients showing an interval between MRI and OCT measurements of more than 200 days were excluded after initial inclusion, and VEP measurements with an interval between MRI and VEP of more than 6 months were not further analysed. A flow chart is presented in Fig. 1. RRMS patients with time since first symptoms of up to 3 years were defined as “early MS”. Neurological disability was rated by the Expanded Disability Status Scale (EDSS) [19], and history of ON was determined clinically by patient history and medical records. Healthy controls comparable to our patient cohort with regard to sex and age served as controls to investigate potential age and sex effects, and underwent 7 T MRI, OCT, and FACT. The study was approved by the local ethics committee and was conducted in accordance to the Declaration of Helsinki in its currently applicable version. All participants gave informed written consent.




Fig. 1 Flow chart

MRI data acquisition

Ultrahigh-field MR images were acquired on a 7 T whole body MR system (Magnetom, Siemens, Erlangen, Germany), using a 24-channel RF coil equipped with one transmit channel (Nova Medical, Wilmington, MA, USA). The imaging protocol included axial T2*w FLASH (TE=25 ms, TR=1,820 ms, acquisition time 12:11 min, in plane spatial resolution=0.5×0.5 mm², slice thickness=2 mm), and fluid attenuated inversion recovery imaging (FLAIR; TE=90 ms, TR=16,000 ms, TI=2,925.5 ms, acquisition time=12:50 min, in plane spatial resolution=1.0×1.0 mm², slice thickness=3 mm).

Algorithms quantifying optic radiation damage

The lesion fraction affecting the OR on consecutively pseudonymised T2*w images was manually delineated by a trained observer unaware of paraclinical (VEP, OCT, FACT) data, and was confirmed by a clinical neuroradiologist with more than 10 years' experience in clinical and scientific MS imaging, who was not aware of paraclinical (VEP, OCT, FACT) and clinical data (disease duration, EDSS) (Fig. 2a–d). For obvious reasons, blinding the MRI reader to MS diagnosis was not possible. The optic radiation lesion volume was calculated using the OsiriX software package (OsiriX Foundation, Geneva, Switzerland, version 3.8.1). The T2*w optic radiation thickness of each hemisphere was quantified in separate analyses (Fig. 2e): for each subject, seven continuous axial slices characterised by a high inter-individual comparability were selected: (i) one slice tangential to the inferior splenium of the corpus callosum and superior of the vein of Galen, (ii) three slices in parallel inferior to the first slice, and (iii) three slices in parallel superior to the first slice. A straight line was plotted orthogonal to the interhemispheric fissure and in parallel to the posterior part of the splenium. This line was propagated to the inferior slices. The observer then measured

the OR thickness twice in an anterior and posterior position (Fig. 2e). Finally, the mean OR thickness for each slice and hemisphere was calculated.

Image analyses

T2 lesion count was determined by counting all T2*w hyperintense brain lesions with a volume of at least three voxel at T2*w FLASH, showing a corresponding signal hyperintensity on FLAIR. Virchow-Robin spaces were excluded by their tubular appearance and FLAIR hypointensity. Lesions were masked manually using OsiriX integrated ROI functions. Third ventricle width and bicaudate ratio were assessed as described previously [20, 21], calculated as a mean value derived from three measurements. Two healthy controls were excluded for technical reasons (missing/modified MR sequence affecting measures of third ventricle width). Automated procedures for brain volume quantification, as routinely used in conventional field strengths, suffered mainly from the magnetic field heterogeneities and thus could not be reliably applied.

MR images of nine MS patients were analysed by a second blinded observer (CR) to estimate inter-rater reliability as a two-way mixed average measure intra-class correlation coefficient (ICC), using the consistency model. We achieved a high inter-rater reliability for OR thickness (ICC=0.972), OR volume (ICC=0.882), third ventricle width (ICC=0.976) and bicaudate ratio (ICC=0.938).

Optical coherence tomography

OCT was performed on non-dilated eyes using a spectral-domain (SD)-OCT device (Heidelberg Spectralis® SD-OCT, Heidelberg Engineering, Heidelberg, Germany). All participants were examined with the peripapillary ring scan, measuring the RNFL thickness encircling the optic nerve head in a diameter of approximately 3.4 mm, forming a composition of




Fig. 2 Focal optic radiation damage. Lesions in MS patients (white arrow) commonly affected the optic radiation as shown here in two exemplary patients (a–d); healthy controls (e) did not present with any OR pathology. The quantified part of the white matter lesion covering the

optic radiation was marked in blue for better visualisation (b, d). In addition, optic radiation thickness was measured in four positions in each of seven consecutive slices (e). *Sequence parameters: 7 T T2*w FLASH, TE=25 ms, TR=1,820 ms, spatial resolution=(0.5×0.5) mm²*

1536 A-scans. All scans were reviewed for correct centring and image quality according to the OSCAR-IB guidelines without knowing 7 T MRI data [22].

Visual perception and VEP

FACT was acquired by trained investigators using the Optec 6500 P system (Stereo Optical, Chicago, IL, USA) with the best correction under photopic conditions (‘daylight’ with target luminance value of 85 cd/m²) not knowing 7 T MRI data, as previously described [23]. VEP measures were recorded from the Oz electrode against a Cz reference electrode following standard checkerboard stimulation. Between 40 and 80 recordings were averaged twice and P100 peak latency was measured.

Statistical analyses

The nasal, superior-temporal and inferior-temporal RNFL-sectors reflect visual information from both hemi-retinae [24]. Therefore, we calculated mean values from both eyes and brain hemispheres.

Group differences were assessed using Mann-Whitney U test (MWU) for age, bicaudate ratio, third ventricle width, RNFL, OR thickness, and Pearson’s Chi squared test (alpha=0.05) for gender. A potential gender-related effect on OR thickness was analysed using MWU. Associations between the variables examined were investigated using Spearman’s correlation and ranked partial correlation.

All analyses were performed in SPSS (version 20, IBM, Somers, NY, USA). *P*-values <0.05 were considered significant. All tests should be understood as exploratory data analyses, as no previous power calculation and adjustments for multiple testing were made.

Results

We prospectively enrolled 30 patients and 12 healthy controls. The patient cohort included 26 RRMS patients, including nine patients with early MS and four patients with CIS. The demographic details are summarised in Table 1. FACT was analysed in 29 patients and 11 healthy controls (median time interval

Table 1 Cohort description

		Healthy controls	Patients	ON	nON
n		12	30	11	19
Sex	female [n]	6	12	4	8
	Chi ²		<i>p</i> =0.55	<i>p</i> =0.51	<i>p</i> =0.67
Age (years)	mean ± SD	34±11	35±8	38±6	34±9
	range	20-54	19-49	29-46	19-49
	MWU		<i>p</i> =0.54	<i>p</i> =0.29	<i>p</i> =0.86
Time since MS diagnosis (years)	mean ± SD	n/a	4.6±4.5	5.6±5.4	3.8±3.8
	range		0.2-14.7	0.2-14.7	0.2-11.3
Time since first symptoms (years)	mean ± SD	n/a	6.4±6.5	9.1±7.9	4.8±5.1
	range		0.1-27.7	0.2-27.7	0.1-14.1
EDSS	Median, range	n/a	1.5	1.5	1.5
			0-4.5	1-4.5	0-4.5

Key: ON, patients with a history of acute optic neuritis; nON, patients without any history of acute optic neuritis; EDSS, Expanded Disability Status Scale; MWU, Mann-Whitney U test; Chi², Pearson's Chi squared test; n/a, not applicable; SD, standard deviation. *p*-values describe differences to healthy controls

between MRI and OCT/FACT 2.6 months, range 0 – 6.4). VEP was performed in 16 patients (median time interval between MRI and VEP 3.2 months, range 0 – 5.2). Group differences for patients/healthy controls as well as ON subgroups are presented in Table 2. In total, we detected 898 white matter lesions in patients with RRMS and CIS on T2*w FLASH images (mean ± SD 30±33, range 1 – 116). Sixteen white matter lesions visible in three healthy controls did not exhibit unusual characteristics. It is noteworthy that all analyses mentioned below should be understood as exploratory in nature.

Evaluation of the optic radiation

T2*w imaging at 7 T visualised the OR with great anatomical detail. Hence, all further analyses were made on 7 T T2*w MR images: the mean OR thickness was 3.9 mm in healthy controls (Fig. 2e), and significantly lower in patients (2.9 mm, *p*<0.001). No gender differences in OR thickness were observed in healthy controls (*p*=0.49) or patients (*p*=0.82), nor did OR thickness decrease with age in healthy controls (*p*=0.27) or patients (*p*=0.22). Likewise, no association between RNFL and OR thickness was found in healthy controls.

Evaluation of optic radiation damage in MS

We found 120 OR lesions (mean OR lesion volume ± SD 142 ±201, range 0 – 632 mm³) in 24/30 patients that were often characterised by a central vein considered typical of MS (Fig. 2a–d) [7, 13, 25]. Involvement of the OR was already detectable in 10 of 13 CIS and early MS patients (mean OR lesion volume ± SD 106±184, range 0 – 531 mm³).

Quantification of T2*w OR lesion volumes (Table 2) confirmed an inverse association between OR lesion volume and thickness (supplemental Fig. 1; Spearman's-Rho -0.614, *p*<0.001). This correlation between OR atrophy and OR

lesion volumes remained significant after correcting for i) brain atrophy reflected by two methods, bicaudate ratio (*p*=0.001) and third ventricle width (*p*=0.001), and ii) for global T2w lesion count (*p*=0.013).

Association between optic radiation damage, OCT, and VEP in MS

We observed an inverse relationship between OR lesion volume and RNFL thickness (Spearman's-Rho -0.640, *p*<0.001, Figs. 3, 4a). Decreased RNFL thickness was also associated with increased bicaudate ratio as measure of brain atrophy (*p*=0.045), and higher T2 lesion count (*p*=0.017). The observed association of RNFL thickness reduction with increasing OR lesion volume remained significant after correcting for brain atrophy determined by both third ventricle width (*p*<0.001) or bicaudate ratio (*p*<0.001), and T2 lesion count (*p*=0.002). Likewise, we observed a significant correlation between OR thickness reduction and RNFL thinning (Spearman's-Rho 0.499, *p*=0.005, adjusted for bicaudate ratio *p*=0.018, adjusted for third ventricle width *p*=0.013, Fig. 4b). Furthermore, VEP latency was prolonged with increasing OR lesion volumes (Spearman's-Rho 0.606, *p*=0.013).

Optic radiation damage is associated with visual dysfunction in MS

When further exploring visual dysfunction in MS patients by automated testing of high and low contrast acuity (Table 2), we observed an association of high OR lesion volume with poor low contrast sensitivity under photopic conditions (Spearman's-Rho -0.429, *p*=0.020). However, the relationship between FACT and OR lesion volume is not necessarily an independent phenomenon. It might well be explained by RNFL thinning, that was also associated with poor low contrast sensitivity (*p*=0.004). Consequently, statistical analysis

Table 2 Group differences

		Healthy controls	All patients	ON	nON
n		12	30	11	19
T2 lesion count	mean \pm SD	1 \pm 4	30 \pm 33	42 \pm 37	23 \pm 28
	range [n]	0-13	1-116 <i>p</i><0.001	6-116 <i>p</i><0.001	1-96 <i>p</i><0.001
Bicaudate ratio	mean \pm SD	10.8 \pm 1.7	8.6 \pm 1.9	8.1 \pm 2.1	8.8 \pm 1.7
	range [mm]	8.6-14.3	5.5-14.5	5.5-11.2	7.0-14.5
	MWU		<i>p</i>=0.001	<i>p</i>=0.016	<i>p</i>=0.002
Third ventricle width	mean \pm SD	2.3 \pm 1.1	3.7 \pm 1.4	4.4 \pm 1.6	3.3 \pm 1.2
	range [mm]	0.8-4.8	1.8-7.8	2.6-7.8	1.8-5.6
	MWU		<i>p</i>=0.001	<i>p</i>=0.001	<i>p</i>=0.012
RNFL	mean \pm SD	98 \pm 9	87 \pm 15	84 \pm 19	89 \pm 13
	range [μ m]	83-119	59-116	59-116	60-109
	MWU		<i>p</i>=0.022	<i>p</i> =0.059	<i>p</i>=0.039
VA	mean \pm SD	1.3 \pm 0.3	1.1 \pm 0.3	1.1 \pm 0.2	1.1 \pm 0.3
	range	0.8-1.6	0.4-1.6	0.8-1.6	0.4-1.6
			<i>p</i> =0.052	<i>p</i> =0.104	<i>p</i> =0.087
FACT 85 cd/m ²	mean \pm SD	2.0 \pm 0.1	1.8 \pm 0.3	1.8 \pm 0.2	1.9 \pm 0.3
	range	1.8-2.2	1.0-2.3 <i>p</i>=0.041	1.5-2.3 <i>p</i>=0.005	1.0-2.3 <i>p</i> =0.256
VEP latency	n	n.d.	16	4	12
	mean \pm SD		108 \pm 9	114 \pm 7	106 \pm 9
	range [ms]		93-123	107-122	93-123
OR lesion volume	mean \pm SD	0	142 \pm 201	226 \pm 241	93 \pm 161
	range [mm ³]		0-632	0-632	0-490
OR thickness	mean \pm SD	3.9 \pm 0.6	2.9 \pm 1.0	2.7 \pm 1.2	3.0 \pm 0.8
	range [mm]	3.0-4.9	0.6-4.7	0.6-4.3	1.4-4.7
	MWU		<i>p</i> <0.001	<i>p</i> =0.011	<i>p</i> =0.001

Key: ON, patients with a history of optic neuritis; nON, patients without any history of acute optic neuritis; RNFL, retinal nerve fibre layer; MWU, Mann-Whitney U test to assess differences between patient subgroups and healthy controls; VA, visual acuity; FACT, functional acuity contrast testing; VEP, visual evoked potentials; OR, optic radiation; SD, standard deviation. Because of technical limitations, we excluded unilateral visual acuity in one patient and unilateral FACT in one control. N.d., not determined. *P*-values describe differences to healthy controls. *P* values <0.05 are considered significant and thus shown in bold

revealed no significant association between OR lesion volume and FACT when factoring RNFL thickness in the statistical model (*p*=0.407).

Optic radiation and retinal damage in patients without history of optic neuritis

OR damage was detectable in 14 of 19 patients without previous history of ON (nON, Table 2). Surprisingly, those patients also showed pronounced OR thinning (mean OR thickness 3.0 mm) in comparison to healthy controls (mean OR thickness 3.9 mm, *p*=0.001, Table 2). Likewise, OR lesion volume in nON was correlated inversely with thinning of both, the RNFL (*p*<0.001) and the OR (*p*=0.035). This relationship was still significant when correcting for T2 lesion count (*p*<0.001), brain atrophy determined by bicaudate ratio (*p*=0.001), and third ventricle width (*p*=0.003). Accordingly, we observed a dependency between higher measures of OR lesion volume and impaired visual function (FACT *p*=0.009) as well as delayed VEP (*p*=0.024) in nON.

Optic radiation and retinal damage in patients with history of optic neuritis

History of simultaneous or sequential bilateral (n=7) and unilateral (n=4) ON was recorded in 11 MS patients. As expected, we did not observe any correlations between OR lesion volume and FACT, VEP, and RNFL measures in MS patients with a history of ON since ON itself may cause severe visual dysfunction and RNFL thinning.

Discussion

Ultrahigh-field MRI offers a distinct visualisation of the OR. Using dedicated morphological imaging of brain (7 T MRI) and retinae (OCT), as well as functional measures (FACT, VEP), we here investigated damage to the visual pathway in MS patients in comparison to healthy controls. We demonstrate that i) focal OR damage is present in earliest disease stages and in the majority of MS patients, and ii) the extent of




Fig. 3 Combined retinal and optic radiation damage in one exemplary MS patient. T2*w imaging visualises MS lesions of the atrophic right OR (*arrowheads*). The contralateral OR exhibits only minor abnormalities on 7 T T2*w images. OCT revealed corresponding RNFL thinning (*arrows*) of the ipsilateral temporal and contralateral nasal hemi-retinae. The nasal hemi-retina of the right eye and the temporal hemi-retina of the left eye present RNFL-thinning to a much lesser extent. One more speculative explanation for corresponding RNFL thinning is trans-synaptic

degeneration remote from the damaged right OR. Following this assumption, bilateral optic neuritis was presumably misdiagnosed in this patient with bilateral visual disturbances and bilateral increased VEP latencies. However, we cannot exclude the possibility of independent phenomena simultaneously affecting the anterior and posterior visual pathway. *Sequence parameters:* 7 T T2*w FLASH, TE=25 ms, TR=1,820 ms, spatial resolution=(0.5×0.5) mm²

focal damage to the posterior visual pathway is associated with thinning of the OR and retinal axonal degeneration.

A histological analysis of a post mortem specimen confirmed that the identified T2*w-hypointense periventricular structures indeed reflect the OR; however, in alignment with other reports [4, 26], these were negative in Prussian blue staining for iron (data not presented), a more common cause of T2*w signal extinction. Thus, the signal extinction of the OR observed at 7 T T2*w sequences may rather reflect anisotropic phase phenomena [27] caused by tightly packed, highly aligned axons with compact myelin. This phase

phenomenon caused by high anisotropy may induce signal loss on T2*w imaging. 7 T gains from substantially increased susceptibility effects in comparison to lower field strengths [4, 5]. Consequently, 7 T T2* offers the unique potential to reveal very small focal lesions affecting the OR in a high in-plane spatial resolution.

A plausible explanation for the observed relationship between region-specific atrophy of the OR and occurrence of lesions within the OR is focal axonal trans-section within MS plaques, as reported by MRI and histological studies to occur in both, active and chronic MS lesions [6, 28].




Fig. 4 Association of optic radiation damage with retinal nerve fibre layer thickness. Quantitative analysis revealed an association between the RNFL thickness and both, OR lesion volume (a), and OR thickness (b)

Although the cross-sectional design of this study may not answer questions about the causality, we hypothesise that our findings on retinal and OR degeneration result from subclinical and potentially independent damage of both, the anterior and the posterior visual pathway. In fact, primary retinal pathology in a small proportion of MS patients was recently discussed [29, 30]. Therefore, one could assume that the relationship between retinal and optic radiation damage results from a common underlying disease process causing axonal damage.

A more speculative explanation is trans-synaptic retrograde degeneration, a phenomenon controversially discussed for decades [31–40], induced by optic radiation damage causing retinal thinning detectable by OCT. In our study, the association between focal tissue destruction in the OR and thinning of the RNFL remained significant even when considering exclusively patients without a history of ON, indicating that retinal axonal degeneration in MS occurs partially independent of ON - a notion also supported by previous OCT studies [14–16, 41]. The fact that no association between OR damage and RNFL thinning was detectable in MS patients with ON supports this assumption as the latter itself may cause substantial RNFL destruction [42]. Furthermore, OR and retinal damage in our study kept their significant association when factoring global brain atrophy and total T2*w lesion load in the statistical models. Hence, clinical and subclinical damage to the anterior and posterior visual pathways appear linked to each other and contribute to the correlation between brain atrophy and retinal degeneration in MS [43, 44]. However, trans-synaptic degeneration in MS remains controversially discussed.

In addition, our data suggest that both retinal and OR damage can cause visual impairment which is in alignment

with previous data demonstrating a correlation of T2*w lesion load [18] or DTI measures such as fractional anisotropy [45, 46] with visual dysfunction.

Future longitudinal studies are warranted to prove the causal relationship between OR damage and visual disability, since in our study the latter was statistically also explicable by RNFL thinning. Given the high number of OR lesions and the association between focal OR damage, visual disability, and delayed VEP in our study, it is nevertheless conceivable that an acute MS plaque within the OR affects visual function or VEP latency. Thus, a proven relationship between visual impairment and optic radiation integrity loss may directly impact clinical decisions.

Some limitations of our exploratory study of a limited sample size with multiple comparisons need to be addressed: Non-uniformities of the magnetic field at 7 T prevented us from performing automated computational white and grey matter volume measurements, nevertheless the reliability of the applied brain atrophy methodology was demonstrated before [20, 21]. We cannot exclude subclinical optic nerve damage, and the inferior part of the Meyer loop was not always visualised due to technical limitations. Furthermore, OR quantification may be influenced by MS lesions.

In summary, our study revealed a high prevalence of focal OR damage in MS from the earliest clinical stages correlating with visual dysfunction, VEP latency and retinal axonal damage. Hence, acute lesions affecting the optic radiation should be considered when diagnosing patients suffering from bilateral visual disturbances.

Acknowledgements This work was supported by the German Research Foundation (DFG Exc 257). Our technicians and study nurses

Antje Els, Susan Pikol, Cynthia Kraut, and Gritt Stoffels gave invaluable support.

The scientific guarantor of this publication is Jens Wuerfel.

The authors of this manuscript declare relationships with the following companies: TS received a travel grant from Bayer and Genzyme as well as speaker honoraria from Novartis. TO has nothing to disclose. IM received payments for lectures from Teva, Biogen Idec, and Sanofi as well as travel/accommodation/meeting expenses from Biogen Idec and Bayer. HZ has nothing to disclose. CFP has received travel grants from Teva. LH has received speaker honoraria from Biogen Idec, Bayer, Novartis, Merck-Serono, and Talecris. He serves on the advisory board for Biomarin and has received research support from Biogen and Bayer. KR has received travel grants and speaker honoraria from Merck-Serono, Biogen Idec, Bayer, and Novartis, and receives research support from Novartis. KH has nothing to disclose. WB received grants from Teva, Biogen Idec, Novartis, and Bayer. He also received honoraria for talks from Bayer, Biogen Idec, Merck-Serono, Teva, Genzyme, and Novartis and is member of the company advisory boards of Teva/Sanofi, Novartis, and Biogen Idec. TN is founder of MRI.TOOLS GmbH, Berlin, Germany and received speaker honoraria from Siemens Healthcare, Erlangen, Germany. AUB is cofounder and director of Motognosis UG (haftungsbeschränkt) and has received speaker honoraria, research grants and travel support from Bayer, Biogen Idec, Novartis Pharma, and Heidelberg Engineering. FP has received speaker honoraria, travel grants and research grants from Teva/Sanofi, Bayer, Merck-Serono, Biogen Idec, and Novartis. FP is supported by the German Research Foundation (Exc 257) and has received travel reimbursement from the Guthy Jackson Charitable Foundation. JD receives research grants from Novartis and Bayer, and has received travel support from Novartis, Teva, Bayer, and Merck-Serono, honoraria for consultancy from Bayer, Genzyme, and Teva, and speaker honoraria from Bayer, Teva, Genzyme, and Novartis. JW serves for a Novartis advisory board, received a Novartis research grant, and speaker honoraria from Novartis, Bayer, and Biogen Idec. He is supported by the German ministry for science and research (BMBF/KKNMS).

This study has received funding by the German Research Foundation (DFG Exc 257) and by a restricted research grant from TEVA Pharma, Germany.

One of the authors (Alexander U. Brandt) has significant statistical expertise.

Institutional review board approval was obtained.

Written informed consent was obtained from all subjects (patients) in this study.

Methodology: prospective cross sectional study performed at one institution.

References

- Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol* 69:292–302
- Filippi M, Bozzali M, Rovaris M et al (2003) Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. *Brain* 126:433–437
- Oberwahrenbrock T, Ringelstein M, Jentschke S et al (2013) Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. *Mult Scler* 19:1887–1895
- Kitajima M, Korogi Y, Takahashi M, Eto K (1996) MR signal intensity of the optic radiation. *AJNR Am J Neuroradiol* 17:1379–1383
- Bürgel U, Mecklenburg I, Blohm U, Zilles K (1997) Histological visualization of long fiber tracts in the white matter of adult human brains. *J Hirnforsch* 38:397–404
- Sinnecker T, Mittelstaedt P, Dörr J et al (2012) Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study. *Arch Neurol* 69:739–745
- Kollia K, Maderwald S, Putzki N et al (2009) First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T. *AJNR Am J Neuroradiol* 30:699–702
- Kilsdonk ID, Wattjes MP, Lopez-Soriano A et al (2014) Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. *Eur Radiol* 24:841–849
- Kilsdonk ID, de Graaf WL, Barkhof F, Wattjes MP (2012) Inflammation high-field magnetic resonance imaging. *Neuroimaging Clin N Am* 22:135–157
- Tallantyre EC, Dixon JE, Donaldson I et al (2011) Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions. *Neurology* 76:534–539
- Wuerfel J, Sinnecker T, Ringelstein EB et al (2012) Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. *Mult Scler* 18:1592–1599
- Dörr J, Krautwald S, Wildemann B et al (2013) Characteristics of Susac syndrome: a review of all reported cases. *Nat Rev Neurol* 9:307–316
- Sinnecker T, Dörr J, Pfueller CF et al (2012) Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. *Neurology* 79:708–714
- Petzold A, de Boer JF, Schippling S et al (2010) Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. *Lancet Neurol* 9:921–932
- Oberwahrenbrock T, Schippling S, Ringelstein M et al (2012) Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. *Mult Scler Int* 2012:530305
- Trip SA, Schlottmann PG, Jones SJ et al (2005) Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. *Ann Neurol* 58:383–391
- Pueyo V, Martin J, Fernandez J et al (2008) Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis. *Mult Scler* 14:609–614
- Wu GF, Schwartz ED, Lei T et al (2007) Relation of vision to global and regional brain MRI in multiple sclerosis. *Neurology* 69:2128–2135
- Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). *Neurology* 33:1444–1452
- Bermel RA, Bakshi R, Tjoa C et al (2002) Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis. *Arch Neurol* 59:275–280
- Benedict RHB, Bruce JM, Dwyer MG et al (2006) Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. *Arch Neurol* 63:1301–1306
- Tewarie P, Balk L, Costello F et al (2012) The OSCAR-IB consensus criteria for retinal OCT quality assessment. *PLoS One* 7:e34823
- Bock M, Brandt AU, Kuchenbecker J et al (2012) Impairment of contrast visual acuity as a functional correlate of retinal nerve fibre layer thinning and total macular volume reduction in multiple sclerosis. *Br J Ophthalmol* 96:62–67
- Ferreras A, Pablo LE, Garway-Heath DF et al (2008) Mapping standard automated perimetry to the peripapillary retinal nerve fiber layer in glaucoma. *Invest Ophthalmol Vis Sci* 49:3018–3025
- Tallantyre EC, Brookes MJ, Dixon JE et al (2008) Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI. *Neurology* 70:2076–2078
- Ide S, Kakeda S, Korogi Y et al (2012) Delineation of optic radiation and stria of Gennari on high-resolution phase difference enhanced imaging. *Acad Radiol* 19:1283–1289

27. Sukstanskii AL, Yablonskiy DA (2014) On the role of neuronal magnetic susceptibility and structure symmetry on gradient echo MR signal formation. *Magn Reson Med* 71:345–353
28. Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesions of multiple sclerosis. *N Engl J Med* 338:278–285
29. Saidha S, Syc SB, Ibrahim MA et al (2011) Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. *Brain* 134:518–533
30. Brandt AU, Oberwahrenbrock T, Ringelstein M et al (2011) Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. *Brain* 134:e193
31. Cowey A, Alexander I, Stoerig P (2011) Transneuronal retrograde degeneration of retinal ganglion cells and optic tract in hemianopic monkeys and humans. *Brain* 134:2149–2157
32. Dasenbrock HH, Smith SA, Ozturk A et al (2011) Diffusion tensor imaging of the optic tracts in multiple sclerosis: association with retinal thinning and visual disability. *J Neuroimaging* 21:e41–e49
33. Jindahra P, Petrie A, Plant GT (2009) Retrograde trans-synaptic retinal ganglion cell loss identified by optical coherence tomography. *Brain* 132:628–634
34. Evangelou N, Konz D, Esiri MM et al (2001) Size-selective neuronal changes in the anterior optic pathways suggest a differential susceptibility to injury in multiple sclerosis. *Brain* 124:1813–1820
35. Matthews MR, Cowan WM, Powell TP (1960) Transneuronal cell degeneration in the lateral geniculate nucleus of the macaque monkey. *J Anat* 94:145–169
36. Bridge H, Jindahra P, Barbur J, Plant GT (2011) Imaging reveals optic tract degeneration in hemianopia. *Invest Ophthalmol Vis Sci* 52:382–388
37. Sepulcre J, Goñi J, Masdeu JC et al (2009) Contribution of white matter lesions to gray matter atrophy in multiple sclerosis: evidence from voxel-based analysis of T1 lesions in the visual pathway. *Arch Neurol* 66:173–179
38. Pfueller CF, Brandt AU, Schubert F et al (2011) Metabolic changes in the visual cortex are linked to retinal nerve fiber layer thinning in multiple sclerosis. *PLoS One* 6:e18019
39. Gabilondo I, Martínez-Lapiscina EH, Martínez-Heras E et al (2014) Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. *Ann Neurol* 75:98–107
40. Sriram P, Graham SL, Wang C et al (2012) Transsynaptic retinal degeneration in optic neuropathies: optical coherence tomography study. *Invest Ophthalmol Vis Sci* 53:1271–1275
41. Klistorner A, Garrick R, Barnett MH et al (2013) Axonal loss in non-optic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. *Neurology* 80:242–245
42. Zimmermann H, Freing A, Kaufhold F et al (2013) Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. *Mult Scler* 19:443–450
43. Gordon-Lipkin E, Chodkowski B, Reich DS et al (2007) Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. *Neurology* 69:1603–1609
44. Dörr J, Wernecke KD, Bock M et al (2011) Association of retinal and macular damage with brain atrophy in multiple sclerosis. *PLoS One* 6:e18132
45. Reich DS, Smith SA, Gordon-Lipkin EM et al (2009) Damage to the optic radiation in multiple sclerosis is associated with retinal injury and visual disability. *Arch Neurol* 66:998–1006
46. Kolbe SC, Marriott M, van der Walt A et al (2012) Diffusion tensor imaging correlates of visual impairment in multiple sclerosis and chronic optic neuritis. *Invest Ophthalmol Vis Sci* 53:825–832